Symptoms and quality of life in patients with suspected angina undergoing CT coronary angiography: a randomised controlled trial

Williams, Michelle C., Hunter, Amanda, Shah, Anoop, Assi, Valentina, Lewis, Stephanie, Mangion, Kenneth, Berry, Colin, Boon, Nicholas A., Clark, Elizabeth, Flather, Marcus, Forbes, John, McLean, Scott, Roditi, Giles, van Beek, Edwin J. R., Timmis, Adam D. and Newby, David E. (2017) Symptoms and quality of life in patients with suspected angina undergoing CT coronary angiography: a randomised controlled trial. Heart, 103 (13). pp. 995-1001. ISSN 1355-6037

[thumbnail of Published manuscript]
Preview
PDF (Published manuscript) - Published Version
Available under License Creative Commons Attribution.

Download (334kB) | Preview

Abstract

Background In patients with suspected angina pectoris, CT coronary angiography (CTCA) clarifies the diagnosis, directs appropriate investigations and therapies, and reduces clinical events. The effect on patient symptoms is currently unknown. Methods In a prospective open-label parallel group multicentre randomised controlled trial, 4146 patients with suspected angina due to coronary heart disease were randomised 1:1 to receive standard care or standard care plus CTCA. Symptoms and quality of life were assessed over 6 months using the Seattle Angina Questionnaire and Short Form 12. Results Baseline scores indicated mild physical limitation (74±0.4), moderate angina stability (44±0.4), modest angina frequency (68±0.4), excellent treatment satisfaction (92±0.2) and moderate impairment of quality of life (55±0.3). Compared with standard care alone, CTCA was associated with less marked improvements in physical limitation (difference −1.74 (95% CIs, −3.34 to −0.14), p=0.0329), angina frequency (difference −1.55 (−2.85 to −0.25), p=0.0198) and quality of life (difference −3.48 (−4.95 to −2.01), p<0.0001) at 6 months. For patients undergoing CTCA, improvements in symptoms were greatest in those diagnosed with normal coronary arteries or who had their preventative therapy discontinued, and least in those with moderate non-obstructive disease or had a new prescription of preventative therapy (p<0.001 for all). Conclusions While improving diagnosis, treatment and outcome, CTCA is associated with a small attenuation of the improvements in symptoms and quality of life due to the detection of moderate non-obstructive coronary artery disease.

Item Type: Article
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups: Faculty of Medicine and Health Sciences > Research Groups > Cardiovascular and Metabolic Health
Faculty of Medicine and Health Sciences > Research Groups > Norwich Clinical Trials Unit
Faculty of Medicine and Health Sciences > Research Groups > Public Health and Health Services Research
Related URLs:
Depositing User: Pure Connector
Date Deposited: 09 Mar 2017 01:42
Last Modified: 21 Oct 2022 11:30
URI: https://ueaeprints.uea.ac.uk/id/eprint/62922
DOI: 10.1136/heartjnl-2016-310129

Actions (login required)

View Item View Item